Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s share price dropped 5.9% during mid-day trading on Friday . The company traded as low as $19.10 and last traded at $19.50. Approximately 2,141,818 shares were traded during mid-day trading, an increase of 97% from the average daily volume of 1,087,181 shares. The stock had previously closed at $20.73.

SPPI has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating on shares of Spectrum Pharmaceuticals in a report on Friday, November 3rd. Jefferies Group LLC set a $9.00 target price on Spectrum Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 25th. Zacks Investment Research cut Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Finally, BidaskClub cut Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Spectrum Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $21.40.

The company has a quick ratio of 4.89, a current ratio of 5.04 and a debt-to-equity ratio of 0.33.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.06). The business had revenue of $36.40 million for the quarter, compared to the consensus estimate of $33.27 million. Spectrum Pharmaceuticals had a negative return on equity of 29.73% and a negative net margin of 58.94%. The firm’s revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.07) earnings per share. analysts predict that Spectrum Pharmaceuticals, Inc. will post -1.03 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Spectrum Pharmaceuticals by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 7,292,704 shares of the biotechnology company’s stock worth $54,331,000 after acquiring an additional 83,981 shares during the last quarter. Renaissance Technologies LLC grew its position in Spectrum Pharmaceuticals by 6.9% during the 2nd quarter. Renaissance Technologies LLC now owns 6,071,817 shares of the biotechnology company’s stock worth $45,235,000 after acquiring an additional 392,017 shares during the last quarter. State Street Corp grew its position in Spectrum Pharmaceuticals by 28.3% during the 2nd quarter. State Street Corp now owns 3,020,563 shares of the biotechnology company’s stock worth $22,507,000 after acquiring an additional 666,605 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Spectrum Pharmaceuticals by 21.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,674,679 shares of the biotechnology company’s stock worth $19,926,000 after acquiring an additional 463,434 shares during the last quarter. Finally, Macquarie Group Ltd. grew its position in Spectrum Pharmaceuticals by 9.4% during the 2nd quarter. Macquarie Group Ltd. now owns 2,247,493 shares of the biotechnology company’s stock worth $16,744,000 after acquiring an additional 193,883 shares during the last quarter. Institutional investors and hedge funds own 56.04% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/17/spectrum-pharmaceuticals-inc-sppi-trading-down-5-9.html.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Receive News & Stock Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.